2. Search Result
Search Result
Results for "

podocyte

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

7

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112879
    Mito-TEMPO
    Maximum Cited Publications
    164 Publications Verification

    		 Calcium Channel PINK1/Parkin Mitochondrial Metabolism Apoptosis Autophagy NOD-like Receptor (NLR) Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
    Mito-TEMPO
  • HY-B0561
    Spironolactone
    5+ Cited Publications

    SC9420

    		 Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca 2+ channels to exert antihypertensive effects .
    Spironolactone
  • HY-13306
    Pyrintegrin
    4 Publications Verification

    		 Integrin Metabolic Disease
    Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic .
    Pyrintegrin
  • HY-122051
    AC1903
    1 Publications Verification

    		 TRP Channel Metabolic Disease
    AC1903 is a specific and selective inhibitor of TRPC5 and has podocyte-protective properties. AC1903 does no effects on TRPC4 or TRPC6 currents and shows no off-target effects in kinase profiling assays. AC1903 suppresses severe proteinuria and prevents podocyte loss in focal segmental glomerulosclerosis (FSGS) rat model .
    AC1903
  • HY-16659
    EHT 1864
    20+ Cited Publications

    		 Ras Neurological Disease Cancer
    EHT 1864 is an inhibitor of Rac family small GTPases. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation. The Kd values are 40, 50, 60, and 230 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. EHT 1864 also potently inhibits other Rac-dependent transformation processes, Tiam1- and Ras-mediated growth transformation. EHT 1864 prevents Aβ 40 and Aβ 42 production in vivo. EHT 1864 dependently suppresses the release of migrasomes from podocytes induced by LPS, PAN, or HG .
    EHT 1864
  • HY-N2995
    Poricoic acid A
    1 Publications Verification

    Poricoic acid A(F)

    		 NF-κB Keap1-Nrf2 AMPK TGF-beta/Smad Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Poricoic acid A can be isolated from Poria cocos. Poricoic acid A is an orally active anti-tumor agent. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Poricoic acid A also attenuatea fibroblast activation and abnormal extracellular matrix remodeling in renal fibrosis by activating AMPK and inhibiting Smad3. Poricoic acid A significantly reduces the magnitude of rise in serum creatinine and urea levels in rat model when combined with Melatonin. Poricoic acid A ameliorates renal fibrosis and podocyte injury by attenuating oxidative stress and inflammation through regulating NF-κB and Nrf2 in IRI rodent model in combination with Melatonin .
    Poricoic acid A
  • HY-101986
    BIIE-0246
    2 Publications Verification

    AR-H 053591

    		 Neuropeptide Y Receptor Metabolic Disease Endocrinology
    BIIE-0246 (AR-H 053591) is a potent and selective NPY2R (neuropeptide Y receptor 2) antagonist with an IC50 value of 15 nM for rat [ 125I]PYY3-36. BIIE-0246 decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated. BIIE-0246 reduces albuminuria in ADR nephropathy .
    BIIE-0246
  • HY-N9480
    Vinaxanthone
    3 Publications Verification

    SM-345431

    		 Phospholipase Bacterial Infection Cancer
    Vinaxanthone (SM-345431) is a potent and selective semaphorin3A, phospholipase C (PLC) and FabI inhibitor, with IC50s of 0.1-0.2 μM and 0.9 mM for semaphorin3A and FabI. Vinaxanthone inhibits the substrate (t-o-NAC thioester) and the cofactor (NADPH) with Kis of 3.1 μM and 1.0 μM, respectively. Vinaxanthone can be used to handle infections caused by multidrug-resistant pathogens .
    Vinaxanthone
  • HY-125944
    MitoTEMPO hydrate
    Maximum Cited Publications
    164 Publications Verification

    		 Mitochondrial Metabolism PINK1/Parkin NOD-like Receptor (NLR) Autophagy Calcium Channel Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
    MitoTEMPO hydrate is a mitochondria-targeted antioxidant . MitoTEMPO hydrate induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. MitoTEMPO hydrate regulates Ca 2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. MitoTEMPO hydrate reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. MitoTEMPO hydrate can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke .
    MitoTEMPO hydrate
  • HY-B1546A
    Benzamil hydrochloride
    1 Publications Verification

    Benzylamiloride hydrochloride

    		 Na+/Ca2+ Exchanger Sodium Channel Neurological Disease
    Benzamil hydrochloride (Benzylamiloride hydrochloride), an Amiloride analogue, is a Na +/Ca 2+ exchanger (NCX) inhibitor (IC50~100 nM). Benzamil hydrochloride also is a non-selective Deg/epithelial sodium channels (ENaC) blocker, and can potentiate myogenic vasoconstriction. Benzamil hydrochloride inhibits TRPP3-mediated Ca 2+-activated currents, with an IC50 of 1.1 μM .
    Benzamil hydrochloride
  • HY-135470
    Nifurpirinol
    1 Publications Verification

    P-7138

    		 Bacterial Infection
    Nifurpirinol (P-7138) is a selective prosubstrate of bacterial nitroreductase (NTR). NTR catalyzes the reduction of nifurpirinol to generate cytotoxic metabolites that induce apoptosis in target cells. Nifurpirinol selectively ablates NTR-expressing cells such as pancreatic β cells, osteoblasts, dopaminergic neurons, and podocytes in transgenic zebrafish models. Nifurpirinol can be used in regeneration studies and disease modeling such as focal segmental glomerulosclerosis (FSGS) .
    Nifurpirinol
  • HY-120380
    FeTMPyP

    		MOFs PARP Neurological Disease
    FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. FeTMPyP inhibits cell death, nitrotyrosine formation, and depolarization of mitochondrial transmembrane potential. FeTMPyP reduces homocysteine-induced nitrosative stress and partially restores TFEB protein and mRNA levels. FeTMPyP improves functional and behavioral deficits caused by chronic constriction injury in rats. FeTMPyP alleviates acute cerebral infarction in a rat model of middle cerebral artery occlusion with mild hyperglycemia. FeTMPyP can be used in studies related to neuropathic pain, renal aging, ischemic penumbra, and hyperglycemic stroke .
    FeTMPyP
  • HY-P1430
    11R-VIVIT
    5+ Cited Publications

    Cell permeable NFAT inhibitor

    		 Nuclear Factor of activated T Cells (NFAT) Metabolic Disease
    11R-VIVIT is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT can be used for the research of podocyte and diabetic nephropathy .
    11R-VIVIT
  • HY-W012575
    2,4-Dihydroxybenzoic acid

    		Reactive Oxygen Species (ROS) Inflammation/Immunology
    2,4-Dihydroxybenzoic acid is a degradation product of acid cherry anthocyanins during in vitro cell culture and an analogue of coenzyme Q precursor molecules. 2,4-Dihydroxybenzoic acid can improve the related symptoms of kidney diseases caused by ADCK4/Coq6 deficiency .
    2,4-Dihydroxybenzoic acid
  • HY-P11178
    Corisin

    		Apoptosis SARS-CoV Infection Metabolic Disease Inflammation/Immunology
    Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF) .
    Corisin
  • HY-133012
    GFB-8438

    		TRP Channel Neurological Disease
    GFB-8438 is a potent and subtype selective TRPC5 inhibitor, with IC50s of 0.18 and 0.29 μM of hTRPC5 and hTRPC4, respectively. GFB-8438 shows excellent selectivity against TRPC6, other TRP family members, NaV 1.5, as well as limited activity against the hERG channel. GFB-8438 protects mouse podocytes from injury induced by protamine sulfate model .
    GFB-8438
  • HY-128442
    Phenyl sulfate

    Phenyl hydrogen sulfate

    		 Endogenous Metabolite Metabolic Disease
    Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker in diabetic kidney disease .
    Phenyl sulfate
  • HY-P1430A
    11R-VIVIT TFA
    5+ Cited Publications

    Cell permeable NFAT inhibitor TFA

    		 Nuclear Factor of activated T Cells (NFAT) Metabolic Disease
    11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy .
    11R-VIVIT TFA
  • HY-B0561R
    Spironolactone (Standard)
    5+ Cited Publications

    SC9420 (Standard)

    		 Reference Standards Mineralocorticoid Receptor Androgen Receptor Autophagy Metabolic Disease Cancer
    Spironolactone (Standard) is the analytical standard of Spironolactone. This product is intended for research and analytical applications. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes .
    Spironolactone (Standard)
  • HY-N10379
    19-epi-Scholaricine

    		Akt mTOR Apoptosis Reactive Oxygen Species (ROS) CDK Ras HSP VEGFR TNF Receptor Interleukin Related Inflammation/Immunology
    19-epi-Scholaricine is an orally active indole alkaloid. 19-epi-Scholaricine downregulates the expression of profibrotic/apoptotic proteins (HRAS, HSP90AA1, KDR) and upregulates the expression of cell cycle-related protein (CDK2). 19-epi-Scholaricine suppresses ROS production and reduces the release of inflammatory mediators, thereby attenuating podocyte apoptosis, renal inflammation and oxidative stress by inhibiting AKT/mTOR. 19-epi-Scholaricine can be used in the research of chronic glomerulonephritis and membranous nephropathy .
    19-epi-Scholaricine
  • HY-Y0308D
    Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339

    Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339

    		 Biochemical Assay Reagents Endocrinology
    Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms .
    Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339
  • HY-176236
    Lipophagy inducer 1

    		LXR Autophagy Metabolic Disease
    Lipophagy inducer 1 is a lipophagy inducer. Lipophagy inducer 1 has activity of reducing lipid droplet accumulation and rescuing cell death. Lipophagy inducer 1 exerts its effects by activating lipophagy, increasing steady-state autophagosome and regulating the LXR signaling pathway. Lipophagy inducer 1 can be used in the study of diabetic nephropathy (DKD) and other diseases related to lipid metabolism disorders .
    Lipophagy inducer 1
  • HY-B0561S1
    Spironolactone-d3

    SC9420-d3

    		 Isotope-Labeled Compounds Mineralocorticoid Receptor Androgen Receptor Autophagy Metabolic Disease Cancer
    Spironolactone-d3 is the deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes .
    Spironolactone-d3
  • HY-B0561S
    Spironolactone-d7

    SC9420-d7

    		 Isotope-Labeled Compounds Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel Metabolic Disease Cancer
    Spironolactone-d7 is the deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes .
    Spironolactone-d7
  • HY-B1546
    Benzamil

    Benzylamiloride

    		 Na+/Ca2+ Exchanger Sodium Channel Neurological Disease
    Benzamil (Benzylamiloride), an Amiloride analogue, is a Na +/Ca 2+ exchanger (NCX) inhibitor (IC50~100 nM). Benzamil also is a non-selective Deg/epithelial sodium channels (ENaC) blocker, and can potentiate myogenic vasoconstriction. Benzamil inhibits TRPP3-mediated Ca 2+-activated currents, with an IC50 of 1.1 μM .
    Benzamil
  • HY-101986A
    BIIE-0246 hydrochloride
    2 Publications Verification

    AR-H 053591 hydrochloride

    		 Neuropeptide Y Receptor Metabolic Disease
    BIIE-0246 hydrochloride (AR-H 053591 hydrochloride) is a potent and selective NPY2R (neuropeptide Y receptor 2) antagonist with an IC50 value of 15 nM for rat [ 125I]PYY3-36. BIIE-0246 hydrochloride decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated. BIIE-0246 hydrochloride reduces albuminuria in ADR nephropathy .
    BIIE-0246 hydrochloride
  • HY-B0561S4
    Spironolactone-d6-1

    		Isotope-Labeled Compounds Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel Cardiovascular Disease Metabolic Disease Cancer
    Spironolactone-d6-1 is the deuterium labeled Spironolactone (HY-B0561). Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca 2+ channels to exert antihypertensive effects .
    Spironolactone-d6-1
  • HY-N15315
    Triptriolide

    		Apoptosis MAP3K NF-κB Others
    Triptriolide inhibits Puromycin aminonucleoside PAN (HY-15695)-induced apoptosis in mouse podocytes through regulation of Bcl-2 family proteins and inhibition of Caspase-3. Triptriolide promotes the cell survival, protects and restores the podocyte function through activation of TAK1-NF-κB signaling pathway and upregulation of podocin .
    Triptriolide
  • HY-126800
    Glycotriosyl glutamine

    		Transmembrane Glycoprotein Drug Derivative Inflammation/Immunology
    Glycotriosyl glutamine is a synthetic analogue of the Glycopeptide. Glycotriosyl glutamine induces focal glomerulonephritis (FGN) and the appearance of myeloid bodies in the epithelial cells of the podocytes in rats with nephritogenic activity .
    Glycotriosyl glutamine
  • HY-B0561S2
    Spironolactone-d3-1

    SC9420-d3-1

    		 Isotope-Labeled Compounds Mineralocorticoid Receptor Androgen Receptor Autophagy Metabolic Disease Cancer
    Spironolactone-d3-1 is deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes .
    Spironolactone-d3-1
  • HY-B1546AR
    Benzamil hydrochloride (Standard)

    Benzylamiloride hydrochloride (Standard)

    		 Na+/Ca2+ Exchanger Sodium Channel Reference Standards Neurological Disease
    Benzamil (hydrochloride) (Standard) is the analytical standard of Benzamil (hydrochloride). This product is intended for research and analytical applications. Benzamil hydrochloride (Benzylamiloride hydrochloride), an Amiloride analogue, is a Na+/Ca2+ exchanger (NCX) inhibitor (IC50~100 nM). Benzamil hydrochloride also is a non-selective Deg/epithelial sodium channels (ENaC) blocker, and can potentiate myogenic vasoconstriction. Benzamil hydrochloride inhibits TRPP3-mediated Ca2+-activated currents, with an IC50 of 1.1 μM .
    Benzamil hydrochloride (Standard)
  • HY-128442R
    Phenyl sulfate (Standard)

    Phenyl hydrogen sulfate (Standard)

    		 Endogenous Metabolite Reference Standards Metabolic Disease
    Phenyl sulfate (Standard) is the analytical standard of Phenyl sulfate. This product is intended for research and analytical applications. Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker in diabetic kidney disease .
    Phenyl sulfate (Standard)
  • HY-135470R
    Nifurpirinol (Standard)

    P-7138 (Standard)

    		 Reference Standards Bacterial Infection
    Nifurpirinol (P-7138) (Standard) is the analytical standard of Nifurpirinol (HY-135470). This product is intended for research and analytical applications. Nifurpirinol (P-7138) is a selective prosubstrate of bacterial nitroreductase (NTR). NTR catalyzes the reduction of nifurpirinol to generate cytotoxic metabolites that induce apoptosis in target cells. Nifurpirinol selectively ablates NTR-expressing cells such as pancreatic β cells, osteoblasts, dopaminergic neurons, and podocytes in transgenic zebrafish models. Nifurpirinol can be used in regeneration studies and disease modeling such as focal segmental glomerulosclerosis (FSGS) .
    Nifurpirinol (Standard)
  • HY-144429
    TRPC5-IN-4

    		TRP Channel Metabolic Disease
    TRPC5-IN-4 is potent and safe TRPC inhibitor with IC50 value of 14.07 nM and 65 nM for TRPC5 and TRPC4, respectively. TRPC5-IN-4 shows no damage on the cellular component of liver and kidney. TRPC5-IN-4 can be used for the research of chronic kidney disease (CKD) .
    TRPC5-IN-4
  • HY-N12768
    Rhodojaponin VI

    		MDM-2/p53 Notch Calcium Channel Neurological Disease Inflammation/Immunology
    Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G. Don
    (Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the MDM2-Notch1 signalling pathway by reducing MDM2 and Notch1 expression. Rhodojaponin VI indirectly reduces Cav2.2 current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain .
    Rhodojaponin VI
  • HY-101986R
    BIIE-0246 (Standard)

    AR-H 053591 (Standard)

    		 Reference Standards Neuropeptide Y Receptor Metabolic Disease Endocrinology
    BIIE-0246 (Standard) is the analytical standard of BIIE-0246 (HY-101986). This product is intended for research and analytical applications. BIIE-0246 (AR-H 053591) is a potent and selective NPY2R (neuropeptide Y receptor 2) antagonist with an IC50 value of 15 nM for rat [125I]PYY3-36. BIIE-0246 decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated. BIIE-0246 reduces albuminuria in ADR nephropathy .
    BIIE-0246 (Standard)
  • HY-181993
    JNK3-IN-11

    		JNK Cadherin Collagen PAI-1 Endocrinology
    JNK3-IN-11 is a selective JNK3 inhibitor with an IC50 of 2.08 nM. JNK3-IN-11 binds to the JNK3 ATP-binding pocket, forming conserved hydrogen bonds with Met149 and a water-mediated hydrogen bond with Lys93. JNK3-IN-11 suppresses TGF-β1-induced c-Jun phosphorylation, reduces profibrotic markers COL1A1 and PAI-1, restores E-cadherin expression, and has protection against podocyte injure. JNK3-IN-11 can be used for the research of chronic kidney disease .
    JNK3-IN-11
  • HY-181556
    JNK3-IN-10

    		JNK TGF-beta/Smad Cadherin Inflammation/Immunology
    JNK3-IN-10 is a blood-brain barrier-impermeable JNK3 inhibitor (IC50=0.257 nM) with over 400-fold selectivity over JNK1. JNK3-IN-10 blocks the JNK3-mediated signaling pathway downstream of TGF-β1, inhibits TGF-β1-induced phosphorylation of c-Jun, reduces the expression of pro-fibrotic markers, and restores the expression of the epithelial protein E-cadherin. JNK3-IN-10 exhibits low cytotoxicity, anti-fibrotic, cytoprotective and renoprotective effects, and alleviates albuminuria, glomerulosclerosis and podocyte foot process fusion. JNK3-IN-10 can be used for the research of chronic kidney disease, glomerulosclerosis and adriamycin-induced nephropathy .
    JNK3-IN-10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: